The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells
Abstract
Purpose: To determine clinical and immunologic responses to a multipeptide melanoma vaccine regimen, a randomized phase II trial was performed. Patients and Methods: Twenty-six patients with advanced melanoma were randomly assigned to vaccination with a mixture of four gp100 and tyrosinase peptides restricted by HLA-A1, HLA-A2, and HLA-A3, plus a tetanus helper peptide, either in an emulsion with granulocyte-macrophage colony-stimulating factor (GM-CSF) and Montanide ISA-51 adjuvant (Seppic Inc, Fairfield, NJ), or pulsed on monocyte-derived dendritic cells (DCs). Systemic low-dose interleukin-2 (Chiron, Emeryville, CA) was given to both groups. T-lymphocyte responses were assessed, by interferon gamma ELIspot assay (Chiron, Emeryville, CA), in peripheral-blood lymphocytes (PBLs) and in a lymph node draining a vaccine site (sentinel immunized node [SIN]). Results: In patients vaccinated with GM-CSF in adjuvant, T-cell responses to melanoma peptides were observed in 42% of PBLs and 80% of SINs, but in patients vaccinated with DCs, they were observed in only 11% and 13%, respectively. The overall immune response was greater in the GM-CSF arm (P < .02). Vitiligo developed in two of 13 patients in the GM-CSF arm but in no patients in the DC arm. Helper T-cell responses to the tetanus peptide were detected in PBLs after vaccination and correlated with T-cell reactivity to the melanoma peptides. Objective clinical responses were observed in two patients in the GM-CSF arm and one patient in the DC arm. Stable disease was observed in two patients in the GM-CSF arm and one patient in the DC arm. Conclusion: The high frequency of cytotoxic T-lymphocyte responses and the occurrence of clinical tumor regressions support continued investigation of multipeptide vaccines administered with GM-CSF in adjuvant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., & Slingluff, C. L. (1994) · Science · doi:10.1126/science.7513441 · Cited by 824
Self-citationSoiffer, R., Lynch, T., Mihm, M., Jung, K., Rhuda, C., Schmollinger, J. C., Hodi, F. S., Liebster, L., Lam, P., Mentzer, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13141 · Cited by 571
Heufler, C., Koch, F., & Schuler, G. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.700 · Cited by 540
HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation
Henderson, R. A., Michel, H., Sakaguchi, K., Shabanowitz, J., Appella, E., Hunt, D. F., & Engelhard, V. H. (1992) · Science · doi:10.1126/science.1546329 · Cited by 520
Self-citationSkipper, J. C., Hendrickson, R. C., Gulden, P. H., Brichard, V, Van Pel, A., Chen, Y., Shabanowitz, J., Wolfel, T., Slingluff, C. L., Boon, T., et al. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.2.527 · Cited by 405
Self-citationSlingluff, C. L., Yamshchikov, G. V., Neese, P. Y., Galavotti, H., Eastham, S., Engelhard, V. H., Kittlesen, D. J., Deacon, D. H., Hibbitts, S., Grosh, W. W., et al. (2001) · PubMed · Cited by 229
Self-citationKoch, F., Heufler, C., Kämpgen, E., Schneeweiss, D., Böck, G., & Schuler, G. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.1.159 · Cited by 221
Response evaluation criteria in solid tumors (RECIST): New guidelines
Tsuchida, Y., & Therasse, P. (2001) · Medical and Pediatric Oncology · doi:10.1002/mpo.1154 · Cited by 199
Ahlers, J., Dunlop, N. M., Alling, D. W., Nara, P. L., & Berzofsky, J. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.8.3947 · Cited by 154
Delineation of several DR-restricted tetanus toxin T cell epitopes.
Demotz, S., Lanzavecchia, A., Eisel, U. L. M., Niemann, H., Widmann, C., & Corradin, G. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.2.394 · Cited by 139
Kittlesen, D. J., Thompson, L. W., Gulden, P. H., Skipper, J., Colella, T. A., Shabanowitz, J., Hunt, D. F., Engelhard, V. H., & Slingluff, C. L. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.5.2099 · Cited by 132
Self-citationScheibenbogen, C., Schmittel, A. H., Keilholz, U., Allgäuer, T., Hofmann, U., Max, R., Thiel, E., & Schadendorf, D. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200003000-00012 · Cited by 131
Kawakami, Y., Robbins, P. F., Wang, X., Tupesis, J. P., Parkhurst, M. R., Kang, X., Sakaguchi, K., Appella, E., & Rosenberg, S. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.12.6985 · Cited by 115
Skipper, J., Kittlesen, D. J., Hendrickson, R. C., Deacon, D. H., Harthun, N. L., Wagner, S. N., Hunt, D. F., Engelhard, V. H., & Slingluff, C. L. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.5027 · Cited by 100
Self-citationAhmed, F. Y., Leonard, G., A’Hern, R., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.498 · Cited by 13
Schomburg, A., Menzel, T., Körfer, A., et al. (1992) · PubMed · Cited by 12
Cited by
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Exploiting the Mutanome for Tumor Vaccination
Castle, J. C., Kreiter, S., Diekmann, J., Löwer, M., van de Roemer, N., de Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3722 · Cited by 810
Clinical use of dendritic cells for cancer therapy
Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F., & Berneman, Z. N. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70585-0 · Cited by 700
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
Peptide Vaccine: Progress and Challenges
Li, W., Joshi, M., Singhania, S., Ramsey, K., & Murthy, A. (2014) · Vaccines · doi:10.3390/vaccines2030515 · Cited by 679
Metadata
- Authors
- Slingluff, C. L., Petroni, G. R., Yamshchikov, G. V., Barnd, D. L., Eastham, S., Galavotti, H., Patterson, J. W., Deacon, D. H., Hibbitts, S., Teates, D., Neese, P. Y., Grosh, W. W., Chianese-Bullock, K. A., Woodson, E. M. H., Wiernasz, C. J., Merrill, P., Gibson, J., Ross, M., & Engelhard, V. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-11-01
- Volume
- 21
- Issue
- 21
- Pages
- 4016-4026
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2164584613
- Cited by
- 322
- References
- 22
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.